Hanmi Pharm 将来の成長

Future 基準チェック /16

Hanmi Pharm利益と収益がそれぞれ年間7.2%と7.3%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に15.6% 6.8%なると予測されています。

主要情報

7.2%

収益成長率

6.8%

EPS成長率

Pharmaceuticals 収益成長	38.3%
収益成長率	7.3%
将来の株主資本利益率	15.6%
アナリストカバレッジ	Good
最終更新日	03 Nov 2024

今後の成長に関する最新情報

Recent updates

Does Hanmi Pharm (KRX:128940) Have A Healthy Balance Sheet?

Nov 01

Does Hanmi Pharm (KRX:128940) Deserve A Spot On Your Watchlist?

Oct 17

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 36% Below Their Intrinsic Value Estimate

Aug 16

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 22% Below Their Intrinsic Value Estimate

Nov 24

業績と収益の成長予測

KOSE:A128940 - アナリストの将来予測と過去の財務データ ( )KRW Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1,871,781	217,556	259,296	298,647	16
12/31/2025	1,737,155	189,721	236,060	278,800	17
12/31/2024	1,583,600	162,533	247,473	288,725	6
6/30/2024	1,568,781	184,377	198,396	253,078	N/A
3/31/2024	1,533,383	158,086	215,064	266,810	N/A
12/31/2023	1,490,887	146,231	173,029	216,538	N/A
9/30/2023	1,419,708	131,316	93,449	133,068	N/A
6/30/2023	1,397,244	101,982	98,900	139,958	N/A
3/31/2023	1,371,607	106,424	100,087	142,458	N/A
12/31/2022	1,331,547	82,792	111,618	162,269	N/A
9/30/2022	1,330,854	80,780	212,242	258,668	N/A
6/30/2022	1,291,788	78,807	222,898	267,987	N/A
3/31/2022	1,253,997	67,497	242,072	281,103	N/A
12/31/2021	1,203,186	67,025	167,776	201,923	N/A
9/30/2021	1,130,015	77,337	186,309	227,481	N/A
6/30/2021	1,093,865	23,092	145,080	185,482	N/A
3/31/2021	1,057,969	23,462	92,160	139,157	N/A
12/31/2020	1,075,854	11,959	93,785	151,535	N/A
9/30/2020	1,101,450	-1,238	27,417	114,463	N/A
6/30/2020	1,100,225	36,049	-15,536	121,852	N/A
3/31/2020	1,127,208	46,907	-118,323	64,277	N/A
12/31/2019	1,113,650	52,110	-165,540	12,447	N/A
9/30/2019	1,104,465	29,815	-151,837	52,148	N/A
6/30/2019	1,074,014	34,892	-178,529	11,181	N/A
3/31/2019	1,044,929	29,971	-167,121	54,106	N/A
12/31/2018	1,015,962	24,891	-184,829	25,982	N/A
9/30/2018	954,879	41,003	-253,511	-57,022	N/A
6/30/2018	947,203	50,120	-286,240	-61,733	N/A
3/31/2018	928,713	49,170	N/A	-58,807	N/A
12/31/2017	916,586	60,434	N/A	-62,905	N/A
9/30/2017	856,033	12,415	N/A	-499	N/A
6/30/2017	848,177	-3,433	N/A	8,921	N/A
3/31/2017	859,901	4,177	N/A	3,461	N/A
12/31/2016	882,725	23,326	N/A	412,965	N/A
9/30/2016	1,300,579	220,192	N/A	473,881	N/A
6/30/2016	1,349,235	188,682	N/A	439,648	N/A
3/31/2016	1,359,164	179,858	N/A	464,276	N/A
12/31/2015	1,317,535	154,443	N/A	101,712	N/A
9/30/2015	939,070	9,750	N/A	-35,497	N/A
6/30/2015	850,027	37,587	N/A	1,946	N/A
3/31/2015	791,905	33,760	N/A	-35,048	N/A
12/31/2014	761,280	35,510	N/A	-32,820	N/A
9/30/2014	743,779	32,302	N/A	-9,178	N/A
6/30/2014	750,634	45,249	N/A	16,754	N/A
3/31/2014	743,951	45,870	N/A	56,428	N/A
12/31/2013	730,134	43,933	N/A	85,992	N/A

アナリストによる今後の成長予測

収入対貯蓄率: A128940の予測収益成長率 (年間7.2% ) は貯蓄率 ( 2.6% ) を上回っています。

収益対市場: A128940の収益 ( 7.2% ) KR市場 ( 29.4% ) よりも低い成長が予測されています。

高成長収益: A128940の収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: A128940の収益 ( 7.3% ) KR市場 ( 10% ) よりも低い成長が予測されています。

高い収益成長: A128940の収益 ( 7.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: A128940の自己資本利益率は、3年後には低くなると予測されています ( 15.6 %)。

Hanmi Pharm 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Consensus EPS estimates increase by 10%

Consensus EPS estimates increase by 10%

Consensus EPS estimates fall by 12%

Consensus EPS estimates increase by 24%

Consensus EPS estimates increase by 13%

Consensus forecasts updated

Recent updates

Does Hanmi Pharm (KRX:128940) Have A Healthy Balance Sheet?

Hanmi Pharm. Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Does Hanmi Pharm (KRX:128940) Deserve A Spot On Your Watchlist?

GC Biopharma and Hanmi Pharmaceutical Receives IND Clearance for Phase 1/2 Clinical Trial from the U.S. FDA

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 36% Below Their Intrinsic Value Estimate

Pinning Down Hanmi Pharm. Co., Ltd.'s (KRX:128940) P/E Is Difficult Right Now

Hanmi Pharm. Co., Ltd. to Report First Half, 2024 Results on Jul 30, 2024

Do Hanmi Pharm's (KRX:128940) Earnings Warrant Your Attention?

Hanmi Pharm (KRX:128940) Seems To Use Debt Rather Sparingly

Now 23% undervalued after recent price drop

Now 20% undervalued after recent price drop

A Look At The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)

Consensus EPS estimates increase by 10%

Hanmi Pharm. Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Hanmi Pharm. Co., Ltd.'s (KRX:128940) Share Price Not Quite Adding Up

Now 21% undervalued after recent price drop

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Now 22% undervalued

New minor risk - Shareholder dilution

Hanmi Pharm. Co., Ltd. to Report Q4, 2023 Results on Feb 02, 2024

Upcoming dividend of ₩490 per share at 0.2% yield

Consensus EPS estimates increase by 10%

Hanmi Pharm. Co., Ltd. to Report Q3, 2023 Results on Nov 01, 2023

Investor sentiment improves as stock rises 20%

Assertio Holdings, Inc. (NasdaqCM : ASRT) completed the acquisition of Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI).

Consensus EPS estimates fall by 12%

Hanmi Pharm. Co., Ltd. to Report Q2, 2023 Results on Jul 28, 2023

First quarter 2023 earnings released: EPS: ₩3,467 (vs ₩1,566 in 1Q 2022)

Consensus EPS estimates increase by 24%

Investor sentiment improves as stock rises 19%

Full year 2022 earnings: EPS exceeds analyst expectations

Upcoming dividend of ₩490 per share

Less than half of directors are independent

Consensus EPS estimates increase by 13%

Now 25% undervalued after recent price drop

Consensus forecasts updated

Consensus EPS estimates increase by 28%

Less than half of directors are independent

Now 22% undervalued

Upcoming dividend of ₩490 per share

Hanmi Pharmaceutical Finds New Innovative Potential for Efpeglenatide

Price target increased to ₩385,044

Calculating The Intrinsic Value Of Hanmi Pharm. Co., Ltd. (KRX:128940)

Hanmi Pharm. Co., Ltd., Annual General Meeting, Mar 26, 2021

New 90-day low: ₩319,000

Hanmi Pharm (KRX:128940) Use Of Debt Could Be Considered Risky

New 90-day high: ₩405,000

What Percentage Of Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Do Insiders Own?

New 90-day high: ₩394,000

Hanmi Pharm's (KRX:128940) Stock Price Has Reduced 48% In The Past Five Years

New 90-day high: ₩375,000

Hanmi Pharm. Co., Ltd. (KRX:128940) Shares Could Be 22% Below Their Intrinsic Value Estimate

New 90-day high: ₩327,500

Analysts lower EPS estimates to ₩2,279

Analysts update estimates

Price target raised to ₩342,471

New 90-day high - ₩284,500

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘